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Background: Vancomycin is the antibiotic of choice for the treatment of serious infections 
such as methicillin-resistant Staphylococcus aureus (MRSA). Inappropriate prescribing of 
vancomycin can lead to therapeutic failure, antibiotic resistance, and drug toxicity.
Objective: To examine the effectiveness of pharmacist-led implementation of a clinical practice 
guideline for vancomycin dosing and monitoring in a teaching hospital.
Methods: An observational pre–post study design was undertaken to evaluate the implementa-
tion of the vancomycin guideline. The implementation strategy principally involved education, 
clinical vignettes, and provision of pocket guidelines to accompany release of the guideline 
to the hospital Intranet. The target cohort for clinical behavioral change was junior medical 
officers, as they perform the majority of prescribing and monitoring of vancomycin in hospitals. 
Assessment measures were recorded for vancomycin prescribing, therapeutic drug monitoring, 
and patient outcomes.
Results: Ninety-nine patients, 53 pre- and 46 post-implementation, were included in the study. 
Prescribing of a loading dose increased from 9% to 28% (P=0.02), and guideline adherence 
to starting maintenance dosing increased from 53% to 63% (P=0.32). Dose adjustment by 
doctors when blood concentrations were outside target increased from 53% to 71% (P=0.12), 
and correct timing of initial concentration measurement increased from 43% to 57% (P=0.23). 
Appropriately timed trough concentrations improved from 73% to 81% (P=0.08). Pre-dose 
(trough) concentrations in target range rose from 33% to 44% (P=0.10), while potentially toxic 
concentrations decreased from 32% to 21% (P=0.05) post-implementation. Infection cure rates 
for patients increased from 85% to 96% (P=0.11) after the guideline was implemented.
Conclusion: The implementation strategy employed in this study demonstrated potential effec-
tiveness, and should prompt additional larger studies to optimize strategies that will translate 
into improved clinical practice using vancomycin.
Keywords: antibiotics, Australia, behavioral medicine, clinical guidelines, implementation, 
intervention, pharmacists
Introduction
Vancomycin, after nearly 60 years of use, is still the intravenous antibiotic of choice 
for the treatment of methicillin-resistant Staphylococcus aureus (MRSA) infection.1–3 
Inappropriate prescribing of vancomycin is associated with therapeutic failure, antibi-
otic resistance, and kidney toxicity.4 Therapeutic drug monitoring in patients receiving 
vancomycin has been shown to significantly increase clinical efficacy and to decrease 
the rate of kidney toxicity.5 A small number of newer antibiotics for the treatment of 
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Figure 1 Temporal schematic of audits and implementation of vancomycin clinical practice guideline.
Abbreviations: JMO, junior medical officers; Pharm, registered pharmacist.
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MRSA infection have been licensed by the US Food and Drug 
Administration (FDA) in recent years; however, it is critical to 
reserve these agents for when vancomycin fails.6 Development 
of clinical practice guidelines (CPGs) has been identified as 
a way to improve the utilization of vancomycin.7 Education 
and dissemination of CPGs on vancomycin prescribing and 
monitoring are measures to ensure best standard of care for 
patients receiving this antibiotic.8 A previous pilot study where 
a pharmacist implemented vancomycin dosing and monitoring 
guideline in a single surgical unit in our institution, Flinders 
Medical Centre, Bedford Park, South Australia, produced 
favorable and statistically significant results.9 It was unclear if 
a similar implementation strategy targeting physicians working 
in all medical and surgical units across our institution would 
produce similar results to the pilot. The aim of the current 
study was to examine the impact of implementation of a CPG 
for vancomycin dosing and monitoring across all medical and 
surgical units in our institution.
Methods
study design and procedure
The present study was approved by the Southern Adelaide 
Clinical Human Research Ethics Committee (approval 
12312/51711). The ethics application for this study contained 
a waiver of consent as participants were not going to be 
exposed to an increase risk of harm.  The waiver of consent 
was consistent with the National Statement of Ethical Con-
duct in Human Research. The study was an observational pre–
post design undertaken at Flinders Medical Centre, a teaching 
hospital with a wide variety of medical and surgical special-
ties, located in metropolitan South Australia. The study was 
comprised of three phases. Phase 1 was a retrospective audit 
of medical records of patients receiving vancomycin therapy 
over a 3-month consecutive period (pre-implementation). 
Phase 2 was an education program delivered to junior medical 
officers (JMOs) and registered pharmacists, dissemination 
of a pocket version of the guideline to these two groups, and 
release of the CPG to the hospital Intranet.
Pharmacists received education due to their supportive 
role to improve antibiotic use at organizational and prac-
tice level, which has been well documented.10 Release of 
the CPG was accompanied by a formal email sent from the 
hospital Trainee Medical Officer Unit to all JMOs advising 
them of the new guideline and requesting their adherence 
to it. Phase 3 was a subsequent audit of medical records 
of patients receiving vancomycin over a 3-month period 
of the following year (post-implementation) depicted in 
Figure 1. The same months were selected for audit pre- and 
post-implementation to avoid seasonal variance in the use 
of vancomycin. Resource allocation for implementation 
in this study was principally funded through partial salary 
support.
Participants
JMOs
Medical off icers (year 1 post-completion of medical 
school) registered with the Trainee Medical Officer Unit 
in our institution were included in the current study. JMOs 
were the chosen target cohort to measure behavioral change 
in their clinical practice, as they are the medical staff 
principally involved in prescribing, ordering of pathology 
tests, and interpreting test results to inform subsequent 
prescribing and monitoring of the intravenous antibiotic 
vancomycin.
Patients
Patients $18 years of age receiving vancomycin therapy were 
identified from vancomycin blood concentrations recorded in 
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the daily hospital therapeutic drug monitoring report. Patients 
were eligible for inclusion if they had at least one measurable 
vancomycin concentration and had received more than one 
dose of vancomycin.
Intervention
cPg
The vancomycin dosing and monitoring guideline for adults 
that was implemented in this project was a modified version 
of the guideline used in a prior pilot study at our institution.9 
Modifications to the guideline were: 1) an improved deci-
sion support table to assist prescribers to adjust the dose in 
response to results of vancomycin blood concentrations and 
kidney function; and 2) inclusion of an embedded hyperlink 
to a hospital Intranet-based creatinine clearance calculator 
(glomerular filtration rate [GFR] + calculator; Southern 
Adelaide Health Service, Adelaide, SA, Australia) to aid 
doctors to choose an appropriate individualized dose. Also 
included were general explanatory notes on how to use the 
guideline. The amended guideline underwent beta-testing by 
eight JMOs and two final-year medical students from Flinders 
University School of Medicine, co-located in our hospital, 
to ensure the guideline was “fit for purpose”. All JMOs and 
pharmacists were sent an email advising them of the release 
of the guideline and how to access it via the Intranet.
Key features of guideline
Prescribing was as follows: a loading dose of 25 mg/kg actual 
body weight (maximum 2 g vancomycin). Maintenance dosing 
was determined by creatinine clearance (CrCl): .90 mL/min, 
1.5 g vancomycin 12 hourly; CrCl 60–90 mL/min, 1 g van-
comycin 12 hourly; CrCl 20–59 mL/min, 1 g vancomycin 24 
hourly; CrCl ,20 mL/min, 1 g vancomycin every 2–7 days.
Therapeutic drug monitoring was as follows: The time ini-
tial blood concentration was to be measured was determined by 
CrCl; CrCl .60 mL/min required bleeding the patient before 
the fourth dose; CrCl 20–59 mL/min required bleeding the 
patient before the third dose; CrCl ,20 mL/min required bleed-
ing the patient at 48 hours post-dose. Subsequent monitoring 
was stipulated every 48 hours until stable blood concentration 
was achieved (target, 15–20 mg/L); thereafter, patients were to 
be bled twice weekly. Pre-dose (trough) blood concentrations 
were to be taken approximately 1 hour pre-dose.
Implementation process
education
Three 60-minute face-to-face education sessions on van-
comycin prescribing and monitoring were provided to 
JMOs. Pharmacists received two educational sessions. 
Attendance at all education sessions was voluntary, with 
no incentives offered. The tutorial contained content on 
contemporary vancomycin treatment covering issues of 
antibiotic resistance – specifically how subtherapeutic dos-
ing can promote bacterial resistance to vancomycin, the need 
for appropriate dosing, monitoring, issues of vancomycin 
kidney toxicity, and practical advice using clinical vignettes 
on how to determine an appropriate dosage regimen, how to 
monitor, interpret blood concentration results, and how to use 
this information to amend subsequent dosing. Education was 
delivered by the principal investigator, who has expertise in 
clinical education, antibiotics, and therapeutic drug monitor-
ing. Fidelity of the education sessions was ensured by using 
the same content, and clinical vignettes were conducted over 
the same duration for all sessions.
Provision of printed material
A pocket laminated version of the guideline (10 cm ×6 cm), 
suitable for attachment to hospital identification badges, was 
provided to all JMOs and pharmacists.
email alert
All JMOs and pharmacists were sent an email advising 
them of the existence of the guideline and how to access it 
via the Intranet.
assessment measures
Patient characteristics
Medical records were used to extract details of patients; 
residence, comorbidities, and colonization with multi-resistant 
bacterial organisms. Indication for vancomycin, dosage, 
time of dose, and duration were recorded. Concomitant 
aminoglycoside antibiotic use was also recoded, as was the 
treating team (medical or surgical), length of stay in hospital, 
whether surgery was required to help resolve the infection, 
in addition to data on cure and readmission to hospital for 
the same infection. Laboratory data collected included serum 
creatinine (to determine kidney function), vancomycin blood 
concentrations, and microbiological data of organism and 
source of isolate. Vancomycin minimum inhibitory con-
centration (MIC) was determined using a Vitek® 2 compact 
(bioMerieux Inc., Durham, NC, USA) on MRSA isolates 
(when performed by a laboratory).
Clinical behavior of medical officers
Prescribing of vancomycin and ordering of pathology blood 
tests for vancomycin concentrations was assessed by audit 
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of drug charts and medical records. Measurement was con-
ducted on the proportion of patients prescribed: 1) a load-
ing dose, 2) maintenance doses adherent to the guideline, 
3) appropriate dose adjustment (ie, increase or decrease) by 
prescriber in response to blood concentrations of vancomycin 
outside target range, 4) measurement of initial vancomycin 
blood concentration adherent with the guideline (ie, after the 
appropriate number of doses), and 5) appropriately timed 
drawing of blood for vancomycin pre-dose (trough) blood 
concentration in relation to the time of last dose.
Patient outcomes
Electronic hospital pathology database and medical records 
were used to measure: 1) the number of days until patients 
attained a measured vancomycin blood concentration in 
target range, 2) the proportion of vancomycin concentrations 
patients attained within target range, 3) infection cure rates, 
and 4) the frequency of kidney toxicity.
educational attendance and guideline measurement
The number of JMOs and pharmacists that attended educa-
tional sessions on vancomycin dosing and monitoring was 
recorded, as was the frequency of downloads of the guideline 
from the hospital Intranet.
Definitions
Guideline target range for vancomycin blood concentrations 
was 15–20 mg/L.11,12 Kidney toxicity was defined as a rise in 
serum CrCl of $50% or 0.5 mg/dL on 2 or more consecu-
tive days of vancomycin therapy from baseline.13,14 Clinical 
cure was resolution of all clinical and laboratory signs and 
symptoms of infection.15
statistical analysis
Data were stored in Microsoft Excel, and descriptive statis-
tics were used to report results. The IBM Statistical Package 
for the Social Sciences (SPSS) version 22 was used to per-
form statistical testing. The Student’s t-test was performed 
to compare continuous variables, and the chi-square test 
was used to compare categorical variables to measure dif-
ference between the two groups. Observed difference were 
considered statistically significant when P,0.05.16
Results
Patients
There were 99 patients included in this study, with 53 pre- and 
46 post-implementation. The median patient age was 75 years 
vs 63 years, respectively, and median weight was 78 kg vs 77 kg 
in the pre- and post-implementation groups, respectively. Patient 
characteristics are presented in Table 1, while indication for treat-
ment and microbiological data are presented in Table 2.
Clinical behavior of medical officers
Prescribing of vancomycin loading doses increased signifi-
cantly from five (9.43%) to 13 (28.27%) doses (P=0.02). 
The proportion of maintenance doses prescribed that were 
adherent to the guideline increased without significance 
from 52.83% to 63.04% (P=0.32). The frequency of 
prescribers amending (increasing or decreasing) a dose 
when a vancomycin blood concentration was either low 
or high, increased non-significantly from 53.85% pre-
implementation to 70.59% post-implementation (P=0.12). 
The appropriate timing when the initial vancomycin blood 
concentration was measured (after the correct number of 
doses based on kidney function) increased from 43.40% 
to 56.52% post-implementation (P=0.23). Appropriately 
Table 1 Baseline characteristics of patients receiving vancomycin 
treatment
Pre- 
implementation 
n=53 n, (%)*
Post-
implementation 
n=45 n, (%)*
characteristic
 Age years; median (IQR) 75 (59–82) 63 (46–75.5)
 Male sex 32 (60.32) 31 (67.39)
 Residence in RacF 20 (37.73) 10 (67.39)
  Prior admission to  
hospital #12 months
39 (73.58) 31 (67.39)
Prior colonisation with MRO
 In #12 months
  MRsa 20 (37.74) 13 (28.26)
  VRe 11 (20.75) 8 (17.39)
CrCL; median (IQR) 
(mL/min)
77.28 (47.07–109.68) 103.4 (70.63–129.8)
comorbidities
 Diabetes 18 (33.96) 10 (21.74)
 congestive heart failure 6 (11.30) 6 (13.04)
 Ischemic heart disease 10 (18.87) 8 (17.39)
 Valvular disease 5 (9.43) 5 (10.87)
 Malignancy 6 (11.32) 12 (26.09)
Medication
  concomitant 
aminoglycoside
8 (15.09) 15 (32.61)
  Penicillin/beta-lactam  
allergy
20 (37.74) 10 (21.74)
Treating team
 Medical 21 (39.62) 25 (54.35)
 surgical 32 (60.38) 21 (45.65)
Note: *Unless otherwise stated.
Abbreviations: IQR, interquartile range; RACF, residential aged care facility; MRO, 
multi-resistant organism; MRSA, methicillin-resistant Staphylococcus aureus; VRE, 
vancomycin-resistant Enterococcus; CrCl, creatine clearance; min, minute.
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Table 2 Infection site requiring vancomycin treatment and 
microbiological data
Pre-
implementation 
n=53 n, (%)*
Post-
implementation 
n=45 n, (%)*
Infection site
 Bacteremia 15 (11.32) 16 (34.72)
 Synovial/orthopedic 3 (5.66) 2 (4.34)
 CNS/cranial 5 (9.43) 1 (2.17)
 skin and soft tissue infection 17 (32.08) 14 (30.43)
 Osteomyelitis 5 (9.43) 6 (13.04)
 Urinary 1 (1.89) 4 (8.70)
 Respiratory 6 (11.32) 7 (15.21)
 enT 1 (1.89) 0
 GI/abdominal infection 7 (13.2) 2 (4.35)
 Pyrexia of unknown origin 6 (11.32) 3 (6.52)
Bacterial organism#
 MRsa 18/56 (32.14) 13/49 (26.53)
  MIC (mg/L) performed 11/18 (61) 11/13 (85)
    #0.5 4/11 (36) 4/11 (36)
  1.0 5/11 (45) 7/11 (63)
  2.0 2/11 (18) 0
 Enterococcus spp 6/56 (10.71) 8/49 (16.33)
 cons 4/56 (7.14) 5/49 (10.20)
 Staphylococcus epidermis 4/56 (7.14) 5/49 (10.20)
 Mssa 4/56 (7.14) 3/49 (6.12)
 Streptococcus spp 5/56 (8.92) 0
 Other 13/56 (23.2) 8/49 (16.33)
 no growth detected 13/56 (23.2) 8/49 (16.33)
Notes: *Unless otherwise stated; #note, some patients had infection with more 
than one organism. not all MRsa isolates had MIc performed.
Abbreviations: GI, gastrointestinal; Spp, bacterial species; MRSA, methicillin-
resistant Staphylococcus aureus; CoNS, coagulate negative S. aureus; MSSA, methicillin-
sensitive S. aureus; MIC, minimum inhibitory concentration; CNS, central nervous 
system; ENT, ear nose and throat.
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measured pre-dose (trough) vancomycin blood concentra-
tions in relation to the time the previous dose was admin-
istered improved non-significantly from 72.57% to 80.57% 
(P=0.08) (Table 3).
Patient outcomes
The median time for patients to attain an in-target vanco-
mycin trough concentration in their blood decreased from 5 
(interquartile range [IQR] 4.25–13.75) to 4 (IQR, 3–5.5) days 
(P=0.12) post-implementation. The proportion of vancomycin 
blood concentrations in our CPG target range (15–20 mg/L) 
increased non-significantly from 32.93% to 42.55% (P=0.10), 
while the proportion of concentrations in the lower shoulder 
range (10–14.9 mg/L) remained unchanged at 20.73% pre-
implementation and 20.57% post-implementation. Potentially 
kidney toxic concentrations (.20 mg/L) decreased from 52 
(31.37%) to 30 (21.28%) post-implementation (P=0.05). The 
incidence of nephrotoxicity observed did not change from 
11.32% pre- and 10.87% post-implementation.
Sub-analysis found eight of the eleven (72.73%) partici-
pants (four of six pre-and four of five post-implementation) 
with nephrotoxicity had one or more potentially toxic 
vancomycin concentrations .20 mg/L. In contrast, in the 
87 participants without nephrotoxicity, 37 of 87 (42.53%) 
(14 pre- and 23 post-implementation) had one or more van-
comycin concentrations .20 mg/L (P=0.31).
All cures of infection for which vancomycin was prescribed 
increased from 84.48% pre-implementation to 95.83% post-
implementation (P=0.11) (Table 3). Sub-analysis of the three of 
eleven (27.27%) infections that failed to respond to therapy (two 
pre- and one post-implementation) involved patients that had one 
or more sub-therapeutic vancomycin concentrations ,10 mg/L. 
No association was observed between clinical failure and van-
comycin concentrations ,10 mg/L (P=0.33).
educational attendance and guideline process 
measures
Fifty-one of 75 (68%) JMOs registered with the hospital 
Trainee Medical Officer Unit had documented attendance at 
voluntary educational sessions provided on vancomycin dos-
ing and monitoring. Thirty-five of 47 (74%) pharmacists from 
the study site attended an education session. From uploading 
the guideline to the hospital Intranet until the close of the 
study, the guideline had a monthly download mean of 86.5 
(standard deviation [SD] 21.06).
Discussion
The implementation of a vancomycin CPG across medical and 
surgical units was associated with a statistically significant 
increase in the number of patients being prescribed loading 
doses. This result is meaningful, as a recent systematic review 
found that doctors prescribing loading doses of vancomycin 
enabled their patients to more rapidly attain blood target 
levels of vancomycin known to kill bacteria.17 There was a 
non-significant trend to an increase in adherent measurement 
of pre-dose (trough) blood concentrations. This result is also 
meaningful, as it has been previously reported that vancomy-
cin concentrations collected at inappropriate times produce 
spurious results, leading doctors to make incorrect treatment 
decisions.18 There was a substantial reduction of borderline 
significance in the proportion of potentially toxic concentra-
tions (.20 mg/mL), which have been associated with kidney 
toxicity.19–21 This finding warrants further investigation to 
confirm this observation. Doctors’ prescribing of appropriate 
vancomycin maintenance doses increased from approximately 
half to nearly two-thirds (63%) that were guideline-adherent. 
This compares closely with 64% appropriate maintenance 
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Table 3 Clinical behavior of medical officers and patient outcomes
Pre-implementation  
n=53 n, (%)*
Post-implementation 
n=45 n, (%)*
P-values
clinical behaviour
 Prescribing a loading dose 5 (9.43) 13 (28.27) 0.02
 adherent maintenance dose 28 (52.83) 29 (63.04) 0.32
 Dosage adjusted correctly 21/39 (53.85) 24/34 (70.59) 0.12
 adherent timing of initial conc 23 (43.40) 26 (56.52) 0.23
 adherent pre-dose conc 164 (72.57) 26 (80.57) 0.08
Patient outcomes
 Days of admission; median (IQR) 20 (10.5–32.5) 16 (9–29.5) 0.13
 Days of vanco treatment; median (IQR) 10 (4.25–13.75) 6 (4–16.5) 0.31
 Days until first conc in target; median (IQR) 5 (4.25–13.75) 4 (3.5–5.5) 0.12
 conc in target range 54 (32.93) 60 (42.55) 0.10
 Potentially kidney toxic conc 52 (31.37) 30 (21.28) 0.05
 sterile site cure 27/30 (90) 19/19 (100) 0.27
 non-sterile site cure 22/28 (78.57) 27/29 (93.10) 0.14
 all cure of infection 49/58 (84.48) 46/48 (95.83) 0.11
 Kidney toxicity 6 (11.32) 5 (10.87) 1.0
Note: *Unless otherwise stated.
Abbreviations: Conc, blood vancomycin concentration; Vanco, vancomycin; IQR, interquartile range.
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dosing achieved in another study post-implementation of 
vancomycin guidelines,22 and is considerably better than 
(50%) the result that was reported in a study conducted 
in a Hong Kong teaching hospital.23 Post-implementation 
in the current study, there was a much larger improvement in 
dosage adjustments, from 54% pre-implementation to 71% 
post-implementation, made by JMOs when trough concentra-
tions were outside target range, suggesting patients were more 
closely monitored in the current study.
Adherence to the CPG for measurement timing when 
pre-dose (trough) blood concentrations were taken (rela-
tive to time of preceding dose) increased in excess of 80% 
post-implementation in the present study and compared 
similarly (78%) to a study conducted in California that 
implemented vancomycin guidelines.24 While the effect size 
of provision of pocket guidelines is unknown, a Cochrane 
review on the effect of printed educational material on 
professional practice and health care outcomes found 
providing written material to health care staff did have 
a beneficial effect.25 The effect of implementation on the 
proportion of vancomycin concentrations in the target 
range (43%) did reproduce the result observed in the pilot 
study (44%),9 but was non-significant in the current study. 
Forty-three percent of all concentrations within our CPG 
target range highlights the fact that there is still consider-
able work to be done to improve this result; however, some 
authorities use a wider target range (10–20 mg/L),26 and 
when our results were measured against this range, some 
63% of our concentrations were within range.
The rates of nephrotoxicity observed in the present 
study remained encouragingly unchanged despite the post-
implementation group receiving many more loading doses, 
and having double the percentage of patients concomitantly 
receiving aminoglycoside antibiotics, which are also known to 
cause kidney toxicity.27,28 Since the introduction of the CPG, 
the median duration of vancomycin therapy decreased from 
10 days pre-implementation to 6 days post-implementation. 
It is not possible to determine if this reduction was due to 
reasons such as the prescribing of more loading doses, thus 
enabling the antibiotic to act more rapidly, or because doctors 
were requesting blood tests more promptly and were adherent 
to the guideline. The cure rate for both sterile and non-sterile 
infections also improved somewhat post-implementation.
A strength of the guideline implemented in this study is 
that it was based on contemporary international and national 
vancomycin consensus guidelines.11,29 The guideline was 
developed and endorsed by local opinion leaders in the fields 
of pharmacy, infectious diseases, and clinical pharmacology 
from the hospital it was implemented in. This is meaningful, 
as a systematic review of the influence of local opinion lead-
ers showed that their influence was successful in promoting 
evidence-based practice.30 Importantly, the CPG was beta-
tested on JMOs and final-year medical students, who were 
the target audience, and the outcomes used to measure the 
impact of guideline implementation were highly objective. 
Finally, details of the implementation were provided. This is 
important, as it has been reported that studies involving guide-
line implementation often do not provide enough information 
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about the implementation process to be informative to others 
seeking to change practice.31 Further, it has been reported that 
there is an imperfect evidence base in guideline dissemination 
and implementation studies, with little consideration given to 
resource allocation.32 The current study adds to the evidence 
base on this topic.
limitations
The present study has a number of limitations. Review of 
“usual clinical care” paper-based medical records and medica-
tion charts is problematic, as data extraction can be difficult; 
however, the accuracy of research assistants performing data 
collection was audited and was found to be of high accuracy. 
While the educational component of implementation included 
JMOs assigned to various different medical and surgical 
units, the study was conducted in a single hospital, and thus, 
the findings may not necessarily be generalizable. The small 
sample size is a clear limitation. While there was improvement 
in some outcome measures, there is still substantial room for 
improvement. From the attendance records, we were unable to 
confirm if some JMOs or pharmacists went to more than one 
education session, thus potentially reducing the total count 
of professionals receiving education. In addition, there may 
be selection bias in effect, as those professionals that were 
interested to improve their knowledge and skills were the ones 
that attended the educational sessions.
Conclusion
The pharmacist implementation of a CPG across medical 
and surgical units significantly increased the proportion of 
loading doses prescribed by doctors for patients receiving 
vancomycin. A larger-powered study may help determine 
if proportional improvements observed in other measures of 
prescribing and monitoring vancomycin translate into statisti-
cally significant changes in clinical behavior and meaningful 
outcomes for patients and their doctors.
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